Last reviewed · How we verify
Clotrimazole vaginal tablets+ Lactobacillus
Clotrimazole kills vaginal fungi while Lactobacillus restores healthy vaginal microbiota to treat and prevent vaginal yeast infections.
Clotrimazole kills vaginal fungi while Lactobacillus restores healthy vaginal microbiota to treat and prevent vaginal yeast infections. Used for Vaginal candidiasis (yeast infection), Prevention of recurrent vulvovaginal candidiasis.
At a glance
| Generic name | Clotrimazole vaginal tablets+ Lactobacillus |
|---|---|
| Also known as | Clotrimazole vaginal tablets+ Lactobacillus（Umeta-mimi） |
| Sponsor | Peking University Shenzhen Hospital |
| Drug class | Antifungal + probiotic combination |
| Target | Fungal lanosterol 14α-demethylase (CYP51); Lactobacillus competitive exclusion and microbiota restoration |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Clotrimazole is an azole antifungal that disrupts fungal cell membrane synthesis by inhibiting lanosterol 14α-demethylase, effectively killing Candida species. Lactobacillus probiotics restore the normal acidic vaginal environment and competitive flora, reducing recurrence of yeast infections and supporting vaginal health.
Approved indications
- Vaginal candidiasis (yeast infection)
- Prevention of recurrent vulvovaginal candidiasis
Common side effects
- Vulvovaginal irritation or burning
- Vaginal discharge changes
- Local allergic reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: